Difference between revisions of "Afatinib (Gilotrif)"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 10: | Line 10: | ||
*[[Head and neck cancer]] | *[[Head and neck cancer]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 25: | Line 20: | ||
==Also known as== | ==Also known as== | ||
| − | + | *'''Code names:''' BIBW 2992, BIBW-2992 | |
| + | *'''Brand names:''' Afanix, Gilotrif, Giotrif, Tomtovok, Tovok, Xovoltib | ||
==References== | ==References== | ||
| Line 31: | Line 27: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| Line 39: | Line 34: | ||
[[Category:ERBB2 inhibitors]] | [[Category:ERBB2 inhibitors]] | ||
[[Category:ERBB4 inhibitors]] | [[Category:ERBB4 inhibitors]] | ||
| − | |||
[[Category:Head and neck cancer medications]] | [[Category:Head and neck cancer medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Drugs FDA approved in 2013]] | [[Category:Drugs FDA approved in 2013]] | ||
Revision as of 00:13, 27 October 2017
General information
Class/mechanism: Irreversible tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor, ErbB1), HER2 (human epidermal growth factor receptor 2, ErbB2), and HER4 (human epidermal growth factor receptor 4, ErbB4). Inhibition of tyrosine kinase autophosphorylation inhibits ErbB signaling.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Afatinib (Gliotrif) package insert[1]
- Afatinib (Gliotrif) patient drug information (Chemocare)[4]
- Afatinib (Gliotrif) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 7/12/2013: FDA approved for "the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test."
Also known as
- Code names: BIBW 2992, BIBW-2992
- Brand names: Afanix, Gilotrif, Giotrif, Tomtovok, Tovok, Xovoltib